Leadership messaging now central to strategic execution

Tern plc

How leadership communicates is becoming a direct performance lever. Alignment at scale is only possible when communication creates shared meaning. Without that, even strong strategies risk weak execution.

Most companies track internal engagement through surveys, sentiment scores or attendance at events. These metrics offer reach but not clarity. They can show who heard the message, but not whether it was interpreted correctly. That disconnect matters. If staff take different meanings from leadership messages, they make different decisions, and execution drifts.

Message resonance is now a more useful metric. It asks a simple question: are people describing the same message in the same way? When language is consistent across teams, it shows the message has landed. When it isn’t, the gap becomes visible and fixable.

This approach shifts the focus from measuring inputs to tracking understanding. Companies are starting to use unstructured data, employee language in meetings, chat or feedback, to assess how leadership communication is being received and repeated. Analysing these patterns shows where messages are gaining traction, where they’re unclear, and where silence signals disengagement.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Search